Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2026)

Crinetics Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $114.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 20.91% year-over-year to $114.3 million in Q1 2026; TTM through Mar 2026 was $114.3 million, a 20.91% increase from a year earlier, with the FY2025 full-year figure at $101.5 million, down 61.62% from the prior year.
• Cash & Equivalents improved to $114.3 million in Q1 2026 per CRNX's latest filing, from $101.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $395.9 million in Q1 2024 and bottomed at $30.9 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $101.5 million (2025), against an average of $135.6 million.
• Across the five-year window, Cash & Equivalents slumped 83.76% in 2022 and surged 861.14% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $32.7 million in 2022, then jumped by 68.02% to $54.9 million in 2023, then soared by 381.89% to $264.5 million in 2024, then tumbled by 61.62% to $101.5 million in 2025, then grew by 12.61% to $114.3 million in 2026.
• Per Business Quant, the three latest CRNX Cash & Equivalents figures stand at $114.3 million (Q1 2026), $101.5 million (Q4 2025), and $110.9 million (Q3 2025).